TY - JOUR
T1 - Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases
T2 - Results of the KKESH International Collaborative Retina study group
AU - Alshahrani, Saeed T.
AU - Dolz-Marco, Rosa
AU - Gallego-Pinazo, Roberto
AU - Diaz-Llopis, Manuel
AU - Arevalo, J. Fernando
PY - 2016
Y1 - 2016
N2 - Purpose: To evaluate the safety and efficacy of intravitreal dexamethasone implant (Ozurdex) for treating refractory macular edema in retinal vascular diseases. Methods: This is a retrospective consecutive series of 53 eyes with refractory macular edema secondary to central retinal vein occlusion (13 eyes), branch retinal vein occlusion (14 eyes), and diabetic macular edema (26 eyes) treated with a single 0.7 mg dexamethasone implant. Data were collected on best-corrected visual acuity, intraocular pressure, and central macular thickness preoperatively and at 1, 3, and 6 months postoperatively. Results: Baseline best-corrected visual acuity was 20/160 and improved statistically significantly to 20/80 and 20/60 at 1 months and 3 months, respectively (P > 0.05, both postoperative visits), and 20/100 at 6 months (P >0.05). The central macular thickness at baseline was 569.96 ± 178.11 mm, and it decreased statistically significantly to 305.81 ± 155.94 mm, 386 ± 210.79 mm, and 446.41 ± 221.21 mm at 1, 3 and 6 months, respectively (P < 0.05, all visits compared with baseline). Fourteen (26%) eyes developed high intraocular pressure after implantation and was successfully controlled with topical medications, and cataract progressed in 1 (1.8%) eye. Conclusion: The dexamethasone implant improved macular edema in refractory cases resulting in statistically significant improvements in best-corrected visual acuity and central macular thickness that remained stable to 3 months and 6 months, respectively.
AB - Purpose: To evaluate the safety and efficacy of intravitreal dexamethasone implant (Ozurdex) for treating refractory macular edema in retinal vascular diseases. Methods: This is a retrospective consecutive series of 53 eyes with refractory macular edema secondary to central retinal vein occlusion (13 eyes), branch retinal vein occlusion (14 eyes), and diabetic macular edema (26 eyes) treated with a single 0.7 mg dexamethasone implant. Data were collected on best-corrected visual acuity, intraocular pressure, and central macular thickness preoperatively and at 1, 3, and 6 months postoperatively. Results: Baseline best-corrected visual acuity was 20/160 and improved statistically significantly to 20/80 and 20/60 at 1 months and 3 months, respectively (P > 0.05, both postoperative visits), and 20/100 at 6 months (P >0.05). The central macular thickness at baseline was 569.96 ± 178.11 mm, and it decreased statistically significantly to 305.81 ± 155.94 mm, 386 ± 210.79 mm, and 446.41 ± 221.21 mm at 1, 3 and 6 months, respectively (P < 0.05, all visits compared with baseline). Fourteen (26%) eyes developed high intraocular pressure after implantation and was successfully controlled with topical medications, and cataract progressed in 1 (1.8%) eye. Conclusion: The dexamethasone implant improved macular edema in refractory cases resulting in statistically significant improvements in best-corrected visual acuity and central macular thickness that remained stable to 3 months and 6 months, respectively.
KW - DEX implant
KW - Macular edema
KW - Ozurdex
KW - Retina
UR - http://www.scopus.com/inward/record.url?scp=84952890849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952890849&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000000616
DO - 10.1097/IAE.0000000000000616
M3 - Article
C2 - 26079477
AN - SCOPUS:84952890849
SN - 0275-004X
VL - 36
SP - 131
EP - 136
JO - Retina
JF - Retina
IS - 1
ER -